Cargando…
Treatment of keratinocytes with 4-phenylbutyrate in epidermolysis bullosa: Lessons for therapies in keratin disorders
BACKGROUND: Missense mutations in keratin 5 and 14 genes cause the severe skin fragility disorder epidermolysis bullosa simplex (EBS) by collapsing of the keratin cytoskeleton into cytoplasmic protein aggregates. Despite intense efforts, no molecular therapies are available, mostly due to the comple...
Autores principales: | Spörrer, Marina, Prochnicki, Ania, Tölle, Regine C., Nyström, Alexander, Esser, Philipp R., Homberg, Melanie, Athanasiou, Ioannis, Zingkou, Eleni, Schilling, Achim, Gerum, Richard, Thievessen, Ingo, Winter, Lilli, Bruckner-Tuderman, Leena, Fabry, Ben, Magin, Thomas M., Dengjel, Jörn, Schröder, Rolf, Kiritsi, Dimitra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603805/ https://www.ncbi.nlm.nih.gov/pubmed/31078522 http://dx.doi.org/10.1016/j.ebiom.2019.04.062 |
Ejemplares similares
-
Dystrophic Epidermolysis Bullosa: Secondary Disease Mechanisms and Disease Modifiers
por: Nyström, Alexander, et al.
Publicado: (2021) -
Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms
por: Nyström, Alexander, et al.
Publicado: (2015) -
Newer Treatment Modalities in Epidermolysis Bullosa
por: Bruckner-Tuderman, Leena
Publicado: (2019) -
Recent advances in understanding and managing epidermolysis bullosa
por: Kiritsi, Dimitra, et al.
Publicado: (2018) -
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
por: Diociaiuti, Andrea, et al.
Publicado: (2019)